(Q38869465)

English

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

scientific article published on 20 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up (English)

1 reference

Europe PubMed Central

7 September 2017

6

object named as

Alan W Partin

1 reference

Europe PubMed Central

7 September 2017

Patrick Craig Walsh

7

object named as

Patrick C Walsh

1 reference

Europe PubMed Central

7 September 2017

3

object named as

Bruce J Trock

1 reference

Europe PubMed Central

7 September 2017

Mario A Eisenberger

8

object named as

Mario A Eisenberger

1 reference

Europe PubMed Central

7 September 2017

2

object named as

Zhaoyong Feng

1 reference

Europe PubMed Central

7 September 2017

Michael A Carducci

5

object named as

Michael A Carducci

1 reference

Europe PubMed Central

7 September 2017

author name string

Emmanuel S Antonarakis

1

1 reference

Europe PubMed Central

7 September 2017

Elizabeth B Humphreys

4

1 reference

Europe PubMed Central

7 September 2017

publication date

20 July 2011

1 reference

Europe PubMed Central

7 September 2017

BJU International

1 reference

Europe PubMed Central

7 September 2017

109

1 reference

Europe PubMed Central

7 September 2017

32-39

1 reference

Europe PubMed Central

7 September 2017

1

1 reference

Europe PubMed Central

7 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Rising PSA in nonmetastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

9 September 2017

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

14 September 2017

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

14 September 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

25 September 2017

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

17 June 2018

Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

22 August 2018

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

22 August 2018

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

22 August 2018

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204323

22 August 2018

Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21777360

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1464-410X.2011.10422.X

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38869465&oldid=1858228024"